Beta-Blockers for Migraine Prevention: a Review Article
- 172 Downloads
Purpose of review
This review seeks to establish the role of beta-blockers (B-adrenergic receptor antagonists) in the pathophysiology of migraine prophylaxis, compare the efficacy of this group of medications with other common prophylactic agents, and also explore the relative benefits of using individual beta-blockers compared with others.
New evidence supports beta-blockers having several mechanisms of action in migraine prophylaxis. Numerous trials reveal significant clinical differences between various beta-blockers in migraine prophylaxis and that commonly used doses of beta-blockers are not optimal. There are also updated guidelines regarding beta-blocker use in migraine prophylaxis.
Beta-blockers appear to have several mechanisms of action in migraine prophylaxis. We found extensive evidence supporting beta-blockers being effective in migraine prophylaxis. These are often not used at optimum doses; however, when they are, they compare generally favorably compared with other classes of medications. More recent evidence appears to show a relatively favorable side effect profile of beta-blockers compared with previous reports (Barron et al. IJC 163:3572–3579, 2013).
KeywordsBeta-blockers Migraine pathophysiology Migraine prophylaxis
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.• Sprenger T, Viana M, Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics. 2018;15:313–23 A recent and comprehensive review of prophylactic migraine medications and their possible mechanism of action related to migraine pathophysiology.PubMedPubMedCentralCrossRefGoogle Scholar
- 10.•• Jackson J, Cogbill E, Santana-Davila R, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One. 2015;10:7 A very comprehensive systematic meta-analysis of historical and more recent publications observing the efficacy of common prophylactic migraine medications. Includes publications comparing different medications with each other.Google Scholar
- 20.Longmore J, Maguire JJ, Macleod A, et al. Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D receptor agonist sumatriptan and 5-HT in human isolated coronary artery. Br J Clin Pharmacol. 2000;49:126–31.PubMedPubMedCentralCrossRefGoogle Scholar
- 21.Cruickshank JM, Prichard BNC. Beta-blockers in clinical practice. 1st ed. London: Churchill Livingstone; 1988. p. 177–274.Google Scholar
- 23.• Hebestreit J, May A. The enigma of site of action of migraine preventives: no effect of metoprolol on trigeminal pain processing in patients and healthy controls. J Headache Pain. 2017;18:116 A study using fMRI that appears to suggest that the mechanism of action of metoprolol may be peripheral rather than central. The study has some weaknesses; it only observed subjects after 3 months of starting metoprolol, the dose of metoprolol was relatively low at 75mg daily, and it had a small sample size of 45 subjects. However, it still raises some questions as to our current understanding of the mechanism of action of beta-blockers in migraine.PubMedPubMedCentralCrossRefGoogle Scholar
- 25.Pringsheim T, Davenport W, Mackie G, et al. Canadian headache society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39:1–59.Google Scholar
- 27.•• Tfelt-Hansen P, Agesen FN, Furberg N. Pharmacokinetic variability of drugs used for the prophylactic treatment of migraine. CNS Drugs. 2017;31:389–403 Review evaluating the variability in pharmacokinetics amongst prophylactic migraine medications. Highlights the importance of personalized medicine when choosing treatment options in migraineurs.PubMedCrossRefGoogle Scholar
- 28.Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev. 2004;2:CD003225.Google Scholar
- 34.Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2014;251:943–50.Google Scholar
- 36.Tonekaboni SH, Ghazavi A, Fayyazi A, et al. Prophylaxis of childhood migraine: topiramate versus propranolol. Iran J Child Neuro. 2013;7:9–14.Google Scholar
- 51.• Lu H, Kam J, Nordin RB, et al. Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study. J Geriatr Cardiol. 2016;13:749–59 Demonstrates significant risk of symptomatic bradyarrhythmias in older patients. This is important since many patients within this age group (over 64) are currently on beta-blockers for migraine prophylaxis and this risk factor is often not considered.PubMedPubMedCentralGoogle Scholar
- 53.Dickstein K, Cohen-Solal A, Filippatos G, et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–442.PubMedCrossRefGoogle Scholar
- 63.Abramson EA, Arky RA, Woeber KA. Effects of propranolol on the hormonal and metabolic responses to insulin-induced hypoglycaemia. Lancet. 1996;24:21386–8.Google Scholar
- 67.Tfelt-Hansen P. The headaches: β-adrenoceptor blocking drugs in migraine prophylaxis. In: Olesen J, Goadsby P, Ramadan M, et al., editors. The Headaches. 3rd ed. Philadelphia: Lipincott, Williams & Wilkins; 2006.Google Scholar
- 71.Rao BS, Das DG, Taraknath VR, Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India. 2000;48:223–6.Google Scholar
- 75.Palferman TG, Gibberd FB, Simmonds JP. Prophylactic propranolol in the treatment of headache. Br J Clin Pract. 1993;37:28–9.Google Scholar